Alkermes plc has been upgraded from Hold to Buy due to its robust revenue growth driven by the acquisition of Avadel and the launch of Lumryz, which are expected to propel over 20% revenue growth by 2026. The company projects adjusted EBITDA between $370–410 million despite a GAAP net loss. Strong Phase 2 data for Alixorexton in narcolepsy and idiopathic hypersomnia, along with advances in its orexin pipeline, support significant long-term revenue potential. Management changes and steady growth in core products further strengthen Alkermes' strategic position in sleep and central nervous system disorders, indicating a positive outlook.
FS Bancorp, Inc. has appointed Matthew D. Mullet as a director on the boards of both the company and its bank, 1st Security Bank of Washington, effective October 22, 2026. Mullet, who has been President since 2024 and CEO since 2025-2026, brings exte...
The global protein ingredients market, valued at $42.3 billion in 2025, is projected to grow to $65 billion by 2032 with a CAGR of 6.3%. Growth is driven by rising consumer demand for health-focused, protein-enriched foods, sports nutrition, and sust...
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
